


RESEARCH

Open Access



Low-resolution pressure reactivity index and its derived optimal cerebral perfusion pressure in adult traumatic brain injury: a CENTER-TBI study

Lennart Riemann^{1,2}, Erta Beqiri^{2,3}, Peter Smielewski², Marek Czosnyka², Nino Stocchetti^{3,4}, Oliver Sakowitz⁵, Klaus Zweckberger¹, Andreas Unterberg¹, Alexander Younsi^{1*}  and the CENTER-TBI High Resolution ICU (HR ICU) Sub-Study Participants and Investigators

Abstract

Background: After traumatic brain injury (TBI), brain tissue can be further damaged when cerebral autoregulation is impaired. Managing cerebral perfusion pressure (CPP) according to computed “optimal CPP” values based on cerebrovascular reactivity indices might contribute to preventing such secondary injuries. In this study, we examined the discriminative value of a low-resolution long pressure reactivity index (LPRx) and its derived “optimal CPP” in comparison to the well-established high-resolution pressure reactivity index (PRx).

Methods: Using the Collaborative European NeuroTrauma Effectiveness Research in Traumatic Brain Injury (CENTER-TBI) study dataset, the association of LPRx (correlation between 1-min averages of intracranial pressure and arterial blood pressure over a moving time frame of 20 min) and PRx (correlation between 10-s averages of intracranial pressure and arterial blood pressure over a moving time frame of 5 min) to outcome was assessed and compared using univariate and multivariate regression analysis. “Optimal CPP” values were calculated using a multi-window algorithm that was based on either LPRx or PRx, and their discriminative ability was compared.

Results: LPRx and PRx were both significant predictors of mortality in univariate and multivariate regression analysis, but PRx displayed a higher discriminative ability. Similarly, deviations of actual CPP from “optimal CPP” values calculated from each index were significantly associated with outcome in univariate and multivariate analysis. “Optimal CPP” based on PRx, however, trended towards more precise predictions.

Conclusions: LPRx and its derived “optimal CPP” which are based on low-resolution data were significantly associated with outcome after TBI. However, they did not reach the discriminative ability of the high-resolution PRx and its derived “optimal CPP.” Nevertheless, LPRx might still be an interesting tool to assess cerebrovascular reactivity in centers without high-resolution signal monitoring.

(Continued on next page)

* Correspondence: alexander.yousi@med.uni-heidelberg.de

¹Department of Neurosurgery, Heidelberg University Hospital, INF 400, 69120 Heidelberg, Germany

Full list of author information is available at the end of the article



© The Author(s). 2020 **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

(Continued from previous page)

Trial registration: [ClinicalTrials.gov](https://clinicaltrials.gov) Identifier: [NCT02210221](https://clinicaltrials.gov/ct2/show/study/NCT02210221). First submitted July 29, 2014. First posted August 6, 2014.

Keywords: Cerebral autoregulation, Cerebrovascular reactivity, Cerebral perfusion pressure, CPPopt, Traumatic brain injury

Background

Following severe traumatic brain injury (TBI), secondary injury cascades occur that affect cerebral blood flow (CBF). They may lead to ischemia when the cerebral perfusion pressure (CPP), the pressure gradient for cerebral blood flow defined as arterial blood pressure (ABP) minus intracranial pressure (ICP), is too low or to hyperemia and increased ICP when the CPP is too high [1–3]. The brain is vulnerable to changes in CPP after severe TBI because cerebral autoregulation, which normally maintains constant CBF during changes in ABP, is often impaired in those patients [1, 3–5]. A mainstay in the clinical management of TBI is therefore the avoidance of secondary brain injury by controlling ICP and ensuring adequate, non-harmful CBF by regulating CPP. Current guidelines (2016) by the Brain Trauma Foundation recommend keeping CPP between 60 and 70 mmHg [6]. However, likely due to the heterogeneity of cerebral injuries in patients with TBI, a CPP-oriented therapy with one fixed target for all patients failed to demonstrate improved neurological outcome compared to ICP-targeted therapy in a large randomized-controlled trial [7]. This is why a patient-customized approach has been proposed which uses the pressure reactivity index (PRx) to determine the optimal CPP (CPPopt) in an individual patient. The PRx, calculated as a moving correlation coefficient between slow waves of ABP and ICP, is a surrogate marker for cerebral autoregulation and has been associated with outcome after TBI in multiple studies [8–12]. Positive PRx values indicate dysfunctional cerebrovascular reactivity and are associated with increased mortality and unfavorable outcome, while negative values indicate intact pressure reactivity [9]. Using computational methods, this relationship can be exploited to determine an optimal CPP that corresponds to the lowest, most favorable PRx values in a patient [12, 13]. As the PRx and thus CPPopt are derived from ABP and ICP signals that are continuously monitored, the CPPopt recommendation can be constantly updated and refined, thereby providing the possibility to customize the clinical management also over the course of time in an individual patient. The automated CPPopt algorithm introduced by Aries et al. which uses a single, 4-h moving monitoring window to calculate CPPopt has been developed further to a multi-window algorithm.

Deviations of CPP from CPPopt have been shown to correlate with clinical outcome in several retrospective studies [13–15], and the first prospective study assessing the feasibility of clinical management based on continuous determination of CPPopt is currently ongoing (COGiTATE trial) [16]. However, as the PRx and thus PRx-based CPPopt calculations require continuous, full-resolution waveforms of ABP and ICP, the CPPopt concept is currently limited to specialized neurocritical care units. In an attempt to increase accessibility of the PRx concept, a similarly calculated PRx variant called the long pressure reactivity index (LPRx) has been introduced which can be derived from lower resolution, minute-by-minute resampled ICP and ABP signals that standard monitoring devices in most intensive care units (ICU) can provide [17]. However, it remains unclear whether minute-by-minute monitoring might be of high enough resolution to evaluate autoregulation in patients with TBI and derive clinically relevant information from it. In fact, previous studies have yielded mixed results and drawn different conclusions [8, 17–19].

In light of these previous results, we assessed the discriminative value of LPRx and PRx and the performance of the most recent, multi-window CPPopt algorithm currently used in the COGiTATE trial but built on the LPRx instead of the PRx.

Methods

Patient cohort

For this study, all patients from the high-resolution (HR) ICU cohort of the Collaborative European NeuroTrauma Effectiveness Research in TBI (CENTER-TBI) study (EC grant 602150), prospectively recruited between January 2015 and December 2017 at 21 centers in the European Union (EU), were screened and included if they met the following inclusion criteria: (a) availability of high-frequency ICU monitoring data (i.e., continuous ABP and ICP monitoring), (b) availability of Glasgow Outcome Scale Extended (GOSE) at 6 months, (c) age of 18 years or older, and (d) ICP was measured via intraparenchymal probe. During the analysis, 8 patients were excluded from our study because PRx- or LPRx-based CPPopt could not be calculated due to either too short or interrupted monitoring data after artifact removal (3 patients) or very high mean ICP values over the entire

monitoring period exceeding 55 mmHg and resulting in persistent PRx values close to +1, making the CPPopt calculation meaningless (5 patients). For all remaining patients, the following demographic data was retrieved from the CENTER-TBI Neurobot database (version 2.0, CENTER core): age, sex, Glasgow Coma Scale (GCS), GCS–motor component, pupillary response at admission (bilaterally reactive, unilaterally reactive, bilaterally unreactive), and necessity of decompressive surgery (yes/no). For assessment of outcome, the imputed 6-month GOSE variable was used which includes both observed ratings and imputed values. For comparative analyses, patients were dichotomized into fatal vs. non-fatal outcome and unfavorable (GOSE 1–4) vs. favorable (GOSE 5–8) outcome.

ICU monitoring data: recording and processing

High-frequency digital signals from continuous ABP and ICP monitoring during intensive care treatment were recorded for all patients included in this study. Recording was intended to start within 24 h of injury and encompassed the entire time that ICP/ABP monitoring was clinically required. ABP was monitored through radial or femoral arterial lines while ICP was monitored through intraparenchymal ICP probes, parenchymal fiber optic pressure sensors, or external ventricular drains. Signals were either digitally recorded or digitalized via an A/D converter (DT9801; Data Translation, USA MA), hereby sampled at frequency of 100 Hz or higher, using the ICM+ software (Cambridge Enterprise Ltd., UK), a Moberg CNS Monitor (Moberg Research Inc., USA), or a combination of both. Signal artifacts were removed manually and using automated algorithms. Data processing of all monitored signals was conducted using ICM+. Moving averages of 10 s (updated every 10 s) were calculated for ABP, ICP, and CPP (= ABP – ICP). PRx was calculated as a moving Pearson correlation coefficient between 10 s averaged ICP and ABP values in a moving time window of 5 min. For the LPRx, 1-min averages of ICP and ABP were correlated within a moving time window of 20 min. PRx, LPRx, and minute-by-minute averages of ABP and ICP were updated every minute. CPPopt was calculated using a multi-window, weighted approach. Details on the exact ICM+ settings and calculation methods can be found in the COGiTATE protocol paper by Beqiri et al. [16]. In short, a 5-min median CPP time trend was calculated along the PRx (Fisher transformed to achieve normal distribution) and these PRx values were grouped into CPP bins of 5 mmHg (within 40–120 mmHg range). The CPP value corresponding to the lowest associated PRx value was determined using an automatic parabolic curve fitting method. For each time point, this method was conducted for 36 different preceding time windows ranging from 2 to 8 h (with 10-

min increasing steps) in length, resulting in 36 PRx–CPP plots. Following certain inclusion criteria (e.g., rejecting non-physiological values), those 36 different CPPopt values were combined according to particular heuristic weighting rules, which included higher weights given to more recent time windows and rejection of non-parabolic curves, to contribute to the final CPPopt. CPPopt_{LPRx} was calculated accordingly, however using the LPRx instead of PRx. CPPopt_{PRx} and CPPopt_{LPRx} were updated every minute. The difference between median CPP and each computed CPPopt_{PRx}/CPPopt_{LPRx} value was continuously calculated for every minute of the recording period ($\Delta\text{CPPopt}_{\text{PRx}}$, $\Delta\text{CPPopt}_{\text{LPRx}}$). The yield of CPPopt_{PRx}/CPPopt_{LPRx} was defined and calculated as the count of CPPopt values divided by the count of CPP values across the whole recording period. Values of all monitoring parameters (ABP, ICP, PRx, LPRx, CPPopt_{PRx}, CPPopt_{LPRx}, $\Delta\text{CPPopt}_{\text{PRx}}$, $\Delta\text{CPPopt}_{\text{LPRx}}$) were at last averaged over the entire monitoring period for each patient.

Statistical analysis

Demographical variables and ICU monitoring parameters were descriptively analyzed and compared between dichotomized outcome groups using the Mann-Whitney *U* test for continuous variables and the chi-squared test for categorical variables. Results are given as median + interquartile range (IQR), unless stated otherwise. Spearman's rank correlation coefficient was used to evaluate correlation between PRx and LPRx while a Bland-Altman plot was used to assess agreement between both indices. Univariate logistic regression in regard to dichotomized outcomes was applied with either LPRx or PRx as predictors. Discrimination was assessed via area under the receiver operating curve (AUC) and compared using DeLong's test. Multivariate logistic regression was conducted to assess the association between either LPRx or PRx and dichotomized outcomes with adjustment for the IMPACT core variables age, admission GCS motor score (GCS-Motor), and pupil reactivity status (bilaterally reactive, unilateral reactive, bilateral unreactive) [20]. The goodness-of-fit of the full model (IMPACT core variables + LPRx or PRx) was tested against the IMPACT-only model via a likelihood-ratio test, and AUCs were calculated for each model. In all statistical tests, the level of significance was set at 0.05, and no *p* value adjustment for multiple testing was applied due to the exploratory nature of this study. All statistical analyses were performed in the R environment [21].

Results

Patient demographics

A total of 224 patients (176 males and 48 females) ranging in age from 18 to 85 years with a median age of 51

(IQR, 33–64 years) were included in this study. Patient demographics and mean values of ICU monitoring parameters are provided in Table 1. The median GCS score at admission was 6 (IQR, 3–10) with a range from 3 to 15. Decompressive craniectomy was performed in 47 patients during their hospital stay. Six months after admission, 52 patients were dead yielding a mortality rate of 23%. The outcome of 135 patients (60%) was considered unfavorable (i.e., GOSE 1–4) at 6 months post-injury.

PRx and LPRx

Results from Spearman's test showed that there was a significantly positive, albeit only moderate correlation between mean LPRx and PRx values in our patient cohort ($r = 0.63$, $p < 0.001$; Fig. 1a). This correlation was slightly higher for the subgroup of patients with severe TBI ($r = 0.68$, $p < 0.001$). A Bland-Altman plot for agreement between LPRx and PRx yielded a mean bias of 0.076 with 95% limits of agreement at -0.210 and $+0.362$ (Fig. 1b). There was a clear association of higher mortality rates with higher mean LPRx and PRx values, as shown in Fig. 2. Accordingly, both LPRx and PRx were significantly higher in patients with fatal outcome compared to surviving patients (LPRx, 0.025 (-0.096 –

0.212) vs. -0.064 (-0.175 – 0.054), $p < 0.001$; PRx, 0.163 (0.016 – 0.314) vs. 0.009 (-0.082 – 0.112), $p < 0.001$). When dichotomizing patients into unfavorable vs. favorable outcome, a significant group difference could only be detected for the PRx but not for the LPRx (PRx, 0.052 (-0.067 – 0.195) vs. -0.014 (-0.086 – 0.098), $p = 0.013$; LPRx, -0.026 (-0.142 – 0.105) vs. -0.063 (-0.148 – 0.051), $p = 0.204$). In univariate regression analysis, both PRx and LPRx were significantly associated with mortality (Table 2 (A)), which generally increased with higher index values. Discriminative ability was higher for the PRx (AUC 0.70 (0.61 – 0.79), $p < 0.001$) compared to the LPRx (AUC 0.66 (0.58 – 0.75), $p < 0.001$), although this difference did not reach significance in this patient cohort (DeLong's test, $p = 0.348$; Fig. 3a). Interestingly, discriminative ability of both reactivity indices seemed to be particularly strong for the subgroup of patients with severe TBI (LPRx: AUC 0.69 (0.57 – 0.81) and PRx: AUC 0.73 (0.62 – 0.84)). The discriminative value in regard to unfavorable outcome was considerably worse for both indices, and only the PRx reached significance in univariate regression with an AUC of 0.60 (0.52 – 0.67 , $p = 0.007$). However, in comparison to the AUC of LPRx (0.55 (0.47 – 0.63 , $p = 0.102$)), no significant difference could be observed via DeLong's test either ($p = 0.167$).


Similar results were obtained when examining the predictive value of the reactivity indices in relation to patient outcome over the post-traumatic temporal course (Fig. 4a, b). Discrimination tended to be higher for PRx compared to LPRx for both mortality and, with exceptions at days 4 and 5, unfavorable outcome. However, those differences did not reach significance at any observed time point.

When adjusted for age, GCS-Motor, and pupillary response (IMPACT core variables) in multivariate regression analysis, both LPRx and PRx remained independent predictors for mortality (Table 2 (A)). In regard to unfavorable outcome, neither of the indices was found to be a significant predictor in the same multivariate model (PRx: $p = 0.120$ and LPRx: $p = 0.976$). Importantly, when also controlling for ICP and CPP in the multivariate model, only PRx but not LPRx remained significant (Table 2 (C)). Nevertheless, adding either LPRx or PRx to the IMPACT core model led to a notable increase of the AUC for prediction of mortality: 0.78 (0.70 – 0.85) when adding LPRx and 0.80 (0.72 – 0.88) when adding PRx, compared to 0.74 (0.66 – 0.82) for the model without indices (Fig. 3b). For both LPRx and PRx, the goodness-of-fit of the combined IMPACT + index model was significantly improved when compared to the mere IMPACT model as assessed by likelihood-ratio tests ($\chi^2 = 6.79$, $p = 0.009$ (LPRx), and $\chi^2 = 15.13$, $p < 0.001$ (PRx), respectively). Results and trends in our

Table 1 Patient demographics

	All patients
Number of patients	224
Age (years)	51 (33–64)
Sex	
- Female (%)	48 (21%)
- Male (%)	176 (79%)
GCS total	6 (3–10)
GCS motor	4 (1–5)
Pupillary response	
- Both reactive	150 (67%)
- One reactive	17 (8%)
- Both unreactive	39 (17%)
- Unknown	18 (8%)
ABP (mmHg)	83.6 (78.8–90.0)
ICP (mmHg)	12.6 (9.6–16.1)
CPP (mmHg)	71.6 (65.2–77.4)
PRx	0.027 (-0.074 – 0.162)
LPRx	-0.049 (-0.145 – 0.079)
GOSE	3 (3–5)
Unfavorable outcome (%)	135 (60%)
Fatal outcome (%)	51 (23%)

ABP arterial blood pressure, CPP cerebral perfusion pressure, GCS Glasgow Coma Scale, GOSE Glasgow Outcome Scale Extended, ICP intracranial pressure, LPRx long pressure reactivity index, PRx pressure reactivity index



analysis were similar when patients with decompressive surgery were excluded (data not shown).

Optimal cerebral perfusion pressure

Both the LPRx-based and the PRx-based CPPopt calculations produced a similar median CPPopt value in our patient cohort (71.4 (65.9–76.6) mmHg vs. 72.0 (65.9–77.5) mmHg, $p = 0.445$). Correspondingly, we found no significant difference in CPPopt yield between the LPRx- and PRx-based calculations (80.0 (70.4–86.7) % vs. 80.4 (71.4–87.6) %, $p = 0.625$). The difference between CPP and CPPopt_{PRx} ($\Delta\text{CPPopt}_{\text{PRx}}$) was significantly higher in patients with fatal outcome compared to survivors (3.7 (1.9–5.8) mmHg vs. 1.9 (0.9–4.1) mmHg, $p = 0.003$). This relation was also apparent when examining the $\Delta\text{CPPopt}_{\text{LPRx}}$, although it was considerably lower (2.3

(1.0–3.6) mmHg vs. 1.5 (0.7–2.9), $p = 0.049$). $\Delta\text{CPPopt}_{\text{LPRx}}$ and $\Delta\text{CPPopt}_{\text{PRx}}$ were significant predictors of mortality both in univariate and multivariate analyses with age, GCS-Motor, and pupillary as covariates, underlining the association between both CPPopt versions and clinical outcome (Table 2 (B)). However, when also including ICP and CPP in the multivariate model, only $\Delta\text{CPPopt}_{\text{PRx}}$ remained a significant predictor (Table 2 (D)). Still, there was no significant difference between the AUCs of $\Delta\text{CPPopt}_{\text{LPRx}}$ and $\Delta\text{CPPopt}_{\text{PRx}}$ when predicting mortality (0.67 (0.59–0.76) $\Delta\text{CPPopt}_{\text{LPRx}}$ vs. 0.71 (0.62–0.79) $\Delta\text{CPPopt}_{\text{PRx}}$; $p = 0.237$; Fig. 3c). Assessment of the discriminative value of both ΔCPPopt variables over the post-traumatic course did reveal neither a clear increase/decrease over time nor a clear superiority of one ΔCPPopt variable over the other.




Table 2 Results from univariate and multivariate logistic regression analysis in regard to mortality for LPRx, PRx, Δ LPRx-CPPopt, and Δ PRx-CPPopt

A	Parameter	Index: LPRx		Index: PRx	
		Coefficient	<i>p</i> value	Coefficient	<i>p</i> value
Univariate	<i>Index</i>	3.484	< 0.001	4.244	< 0.001
Multivariate	<i>Age</i>	0.039	0.001	0.036	0.003
	<i>GCS-Motor</i>	-0.191	0.068	-0.202	0.059
	<i>Pupillary response</i>	0.304	0.197	0.333	0.173
	<i>Index</i>	2.634	0.011	3.868	< 0.001
B	Parameter	Δ CPPopt: LPRx		Δ CPPopt: PRx	
		Coefficient	<i>p</i> value	Coefficient	<i>p</i> value
Univariate	Δ CPPopt	-0.122	0.003	-0.148	< 0.001
Multivariate	<i>Age</i>	0.049	< 0.001	0.050	< 0.001
	<i>GCS-Motor</i>	-0.196	0.059	-0.227	0.034
	<i>Pupillary response</i>	0.308	0.198	0.257	0.296
	Δ CPPopt	-0.139	0.003	-0.159	< 0.001
	<i>Index</i>	1.628	0.152	3.140	0.007
C	Parameter	Index: LPRx		Index: PRx	
		Coefficient	<i>p</i> value	Coefficient	<i>p</i> value
Univariate	<i>Index</i>	3.484	< 0.001	4.244	< 0.001
Multivariate	<i>Age</i>	0.043	< 0.001	0.039	0.002
	<i>GCS-Motor</i>	-0.164	0.130	-0.169	0.127
	<i>Pupillary response</i>	0.457	0.067	0.474	0.068
	<i>ICP</i>	0.071	0.005	0.061	0.019
	<i>CPP</i>	0.034	0.128	0.035	0.128
	<i>Index</i>	1.628	0.152	3.140	0.007
	<i>Index</i>	1.628	0.152	3.140	0.007
D	Parameter	Δ CPPopt: LPRx		Δ CPPopt: PRx	
		Coefficient	<i>p</i> value	Coefficient	<i>p</i> value
Univariate	Δ CPPopt	-0.122	0.003	-0.148	< 0.001
Multivariate	<i>Age</i>	0.050	< 0.001	0.051	< 0.001
	<i>GCS-Motor</i>	-0.166	0.124	-0.190	0.086
	<i>Pupillary response</i>	0.466	0.067	0.423	0.106
	<i>ICP</i>	0.067	0.009	0.065	0.011
	<i>CPP</i>	0.042	0.066	0.046	0.048
	<i>Index</i>	-0.108	0.065	-0.146	0.002
	<i>Index</i>	-0.108	0.065	-0.146	0.002


Δ CPPopt difference between cerebral perfusion pressure and calculated optimal cerebral perfusion pressure, *GCS-Motor* Glasgow Coma Scale motor component, *LPRx* long pressure reactivity index, *PRx* pressure reactivity index

However, a significant statistical difference could be observed at day 6, with Δ CPPopt_{PRx} displaying a significant higher AUC compared to Δ CPPopt_{LPRx} when predicting death (*p* = 0.007, DeLong’s test; Fig. 4c, d). Similar to our findings with the LPRx and PRx, the goodness-of-fit was significantly improved when adding either Δ CPPopt_{LPRx} or Δ CPPopt_{PRx} to the basic IMPACT model (χ^2 = 9.39, *p* = 0.002 (IMPACT + Δ CPPopt_{LPRx}), and χ^2 = 16.71, *p* < 0.001 (IMPACT + Δ CPPopt_{PRx}); Fig. 3d). The LPRx plus IMPACT model displayed an AUC of 0.77 (0.69–0.85), and the PRx plus IMPACT model an AUC of 0.80 (0.72–0.87). Similar to our previous findings with the

PRx and LPRx, equivalent results were obtained for all CPPopt-associated analyses without including surgically decompressed patients, except for results from the multivariate models including ICP and CPP where Δ CPPopt_{LPRx} remained a significant predictor when only including patients without decompressive craniectomy (data not shown).

Cerebral perfusion pressure targeted therapy

Because a difference of \pm 5 mmHg between the actual CPP and calculated CPPopt has been proposed as an acceptable range for CPP-targeted therapy [12, 16], we




analyzed outcome in a subgroup of patients whose CPP deviated on average by at least ± 5 mmHg from their calculated $\text{CPPopt}_{\text{LPRx}}$ ($n = 32$) and $\text{CPPopt}_{\text{PRx}}$ ($n = 50$, Fig. 5a–d). Of 18 patients with a mean $\Delta\text{CPPopt}_{\text{PRx}} > 5$ mmHg (“hyperperfused” patients), only one patient died (6%). In contrast, 15 of 32 patients with a mean $\Delta\text{CPPopt}_{\text{PRx}} < -5$ mmHg (“hypoperfused” patients) were dead at the 6-month follow-up (47%). The mortality rates differed significantly between those groups ($\chi^2 = 7.24$, $p = 0.007$). According to the calculated $\text{CPPopt}_{\text{LPRx}}$, a mean $\Delta\text{CPPopt}_{\text{LPRx}} > 5$ mmHg was present in 18 patients with the same mortality rate of 6%. However, only 14 patients were determined to be on average at least 5 mmHg below their $\text{CPPopt}_{\text{LPRx}}$ ($\Delta\text{CPPopt}_{\text{LPRx}} < -5$ mmHg), and of those, 5 had died (35%). The mortality rates when comparing “hypo- and hyperperfused” patients according to $\text{CPPopt}_{\text{LPRx}}$ missed statistical significance ($\chi^2 = 2.93$, $p = 0.087$).

Eight of 32 patients (25%) with a mean $\Delta\text{CPPopt}_{\text{PRx}} < -5$ mmHg were severely disabled after 6 months. This proportion was distinctively higher in patients with a mean $\Delta\text{CPPopt}_{\text{PRx}} > 5$ mmHg with 10 of 18 patients (56%), although the rates of severe disability between

those two patient groups did not reach statistical significance ($\chi^2 = 3.44$, $p = 0.064$). Similar results were found for the $\text{CPPopt}_{\text{LPRx}}$: 3 of 14 patients (27%) with a mean $\Delta\text{CPPopt}_{\text{LPRx}} < -5$ mmHg and 10 of 18 patients (56%) with a mean $\Delta\text{CPPopt}_{\text{LPRx}} > 5$ mmHg were severely disabled 6 months after injury ($\chi^2 = 2.52$, $p = 0.113$). Again, similar results were obtained in all statistical tests when only patients without decompressive surgery were considered (data not shown).

Discussion

To individualize therapy is a promising concept for possible reduction of mortality and unfavorable outcome in patients with TBI. Regulating CPP according to computed CPPopt recommendations derived from cerebrovascular reactivity indices might hereby play an important role. However, it remains unclear if high-resolution data for PRx calculation is necessary to obtain relevant CPPopt values or if low-resolution, minute-by-minute signals for LPRx calculation might suffice. This question is particularly important because using the LPRx would make the CPPopt concept available to a wider range of centers and thus patients. The first two




pilot studies examining the LPRx showed encouraging results, stating that LPRx seemed to perform equally well in outcome prediction and CPPopt calculation as the PRx [17, 18]. However, the validity of those studies was limited by relatively small patient numbers (18 and 29, respectively). More recently, a larger (over 300 patients) single-center follow-up study concluded the low-resolution LPRx to be less precise compared to PRx in outcome prediction which our results seem to confirm [8]. The proposed weaker discriminative ability could be further supported by our data especially when ICP and CPP were also added to the IMPACT variables in a multivariate model, where PRx but not LPRx remained a significant predictor. The reason for this inferior performance is likely that the LPRx only includes slower drifts in ABP and ICP which provide less information on the state of autoregulation, as opposed to the PRx which also includes higher frequency wave components, likely representing more outcome-relevant autoregulatory responses.

However, even when performing to some extent worse than the PRx in outcome prediction, the LPRx almost always showed significant results in our analyses as well and the differences of AUCs between PRx and LPRx in univariate regression to mortality were non-significant in

our current work (albeit in a smaller sample). This was also true when comparing the discriminative value of both indices day-by-day during the early post-injury time course (first 6 days).

What is very important is that both indices significantly improved the performance of a multivariable model containing the IMPACT core variables and remained independent predictors for mortality after TBI. However, LPRx lost significance when also adjusting for ICP and CPP. Nevertheless, when taken together, those results seem to support the notion proposed by previous studies [19, 22] that minute-by-minute averaged signals, while performing to some extent weaker, might still carry important outcome-related information and might be sufficient for autoregulation monitoring via pressure reactivity indices. Notably, both indices performed considerably worse when predicting unfavorable outcome compared to predicting mortality, which is also in accordance with previous studies [10, 11]. A subgroup analysis showed an especially strong association with outcome for LPRx/PRx in patients with severe TBI, making our results particularly applicable for such patients.

Given the abovementioned findings, we sought to evaluate the performance of a weighted, multi-window



algorithm for assessing CPPopt that is based on the LPRx instead of the PRx. Determination of CPPopt has the potential to translate the PRx/LPRx concept into clinical management by offering dynamic management targets for CPP according to CPPopt. Ideally, patients might then directly benefit from this individualized therapy. The CPPopt concept built on PRx values has been shown to be of prognostic value in numerous studies in the sense that deviations of CPP from CPPopt were predictors of fatal outcome in TBI patients [12–15, 19, 23]. While the first automated CPPopt algorithm was based on PRx/CPP values in a moving single-window of 4 h for calculation [13], this method was extended to include multiple windows for calculations by Depreitere et al. [19], who used minute-by-minute monitoring data and various low-resolution indices for their approach. They could show that the resulting CPPopt was highly related to outcome and was not inferior in outcome prediction compared to the single-window CPPopt_{PRx} which is based on high-resolution data.

The multi-window concept developed by Depreitere et al. was then adapted to high-resolution data, and thus PRx, and extended with additional weighting and safety criteria as well as more calculation windows in an algorithm implemented in ICM+ by Liu et al. [14], and subsequently modified further to make it suitable for

clinical, bedside application as part of the COGiTATE trial [16]. In our study, we sought to evaluate how the low-resolution LPRx, instead of the PRx, would perform in this most recent CPPopt calculation method. Using the CENTER-TBI high-resolution ICU cohort, we were able to do this in direct reference to the PRx-based approach and in a multi-center dataset. Similar to the LPRx itself, CPPopt_{LPRx} performed slightly worse in outcome prediction than its PRx counterpart but was still a significant predictor for mortality in univariate and multivariate analysis including the IMPACT variables. Both $\Delta\text{CPPopt}_{\text{LPRx}}$ and $\Delta\text{CPPopt}_{\text{PRx}}$ were significant predictors of mortality, even when patients were adjusted for other prognostic factors in multivariate analysis, and their addition to the IMPACT core model could significantly improve the goodness-of-fit. Addition of ΔCPPopt displayed even higher AUCs for mortality than addition of reactivity indices to the model. Interestingly, when also including ICP and CPP in addition to the IMPACT variables in the model, $\Delta\text{CPPopt}_{\text{PRx}}$ remained significant while $\Delta\text{CPPopt}_{\text{LPRx}}$ failed to demonstrate significance in the entire cohort. However, $\Delta\text{CPPopt}_{\text{LPRx}}$ remained significant in non-decompressed patients, indicating a potential use in this patient group. All those results seem to emphasize the importance that the deviation of CPP from CPPopt might have in regard to clinical outcome.

Further studies should examine the extension of the IMPACT core model with autoregulation monitoring indices, analogous to the already present IMPACT core + CT model or IMPACT core + CT + laboratory markers model.

When only patients with a relevant mean CPP/CPPOpt deviation were considered, the CPPOpt_{PRx} method detected more patients overall and showed a closer relation to mortality in patients with an average deviation in CPP of at least 5 mmHg below the PRx-CPPOpt. Even the CPPOpt_{LPRx} showed a substantially higher mortality rate in “hypoperfused” patients when compared to “hyperperfused” ones, although this difference between mortality rates did not reach significance. Similar to Aries et al. [13], we found a higher rate of severe disability in “hyperperfused” patients compared to “hypoperfused” ones. However, this association did not reach significance in our study.

Concerning our results on CPPOpt availability (yield of the algorithm), it has to be mentioned that CPPOpt_{PRx}/CPPOpt_{LPRx} could not be calculated in 8 patients, for reason not related to a failure of the CPPOpt algorithm. In 5 patients, ICP was so high and CPP so low that the autoregulation was completely and entirely lost, and the concept of “optimal” CPP was therefore not applicable. In further 3 patients, there was simply not enough data available to perform the calculation. In all the remaining patients, the fraction of time where CPPOpt could be determined was importantly very similar between CPPOpt_{LPRx} and CPPOpt_{PRx}.

Interestingly, the exclusion of patients who underwent decompressive surgery during their ICU stay did not affect the results in most of our analyses (data not shown), similar to previously published results in other studies. A notable exception is that Δ CPPOpt_{LPRx} remained a significant predictor for mortality in a multivariate model including ICP and CPP only in non-decompressed patients while miss significance in the entire cohort. This is despite the fact that the performance of PRx and thus also LPRx, as the pressure reactivity monitor, depends on reliable transmission of changes in cerebral blood volume into intracranial pressure [24, 25], and that is theoretically adversely affected by the decompressive craniectomy. However, the exact timing of decompressive surgery could play an important role as indices are averaged over the whole monitoring period and future studies should be conducted to examine this relationship closer.

Limitations

As the CENTER-TBI study was designed to be a prospective observational study, treatment strategies and protocols in ICUs might considerably differ between participating centers and might therefore be confounders. Importantly,

ICP and mean arterial pressure (MAP) signals were subject to manipulation by treating clinicians (e.g., actively lowering ICP or MAP in selected patients) and might therefore be also the result of therapeutic interventions. Moreover, this study contains a heterogeneous group of patients in terms of demographics, injury characteristics, and comorbidities which might influence the results. Finally, the considered variables such as the indices and differences between CPP and CPPOpt were averaged over the entire monitoring time per patient which could mean that their variability and the presence of short periods with very deviated values were not accounted for in our analysis. Regarding the temporal course of the discriminative power of both indices, it is important to note that the sample size considerably decreased over time which might influence the results especially at later time points. While this multi-center study can provide evidence for the relevance of LPRx and CPPOpt_{LPRx}, a high-quality, prospective study is needed to conclude whether the CPPOpt_{LPRx} concept can be translated into clinical benefit in patients with TBI.

Conclusions

Our findings indicate that the LPRx and multi-window CPPOpt_{LPRx} do not reach the precision of the PRx and CPPOpt_{PRx} in outcome prediction after TBI. However, the LPRx is still significantly associated with outcome and can produce outcome-relevant CPPOpt values, most reliably in non-decompressed patients. A prospective trial is needed to assess if this association is strong enough for a meaningful clinical translation. Should the ongoing COGiTATE feasibility/safety trial and subsequent phase 3 trials be successful in proving the CPPOpt concept, it might be worthy to consider a respective trial with the CPPOpt_{LPRx} to make the CPPOpt concept available to a broader range of centers and patients.

Abbreviations

ABP: Arterial blood pressure; AUC: Area under the curve; CBF: Cerebral blood flow; CPP: Cerebral perfusion pressure; CPPOpt: Optimal cerebral perfusion pressure; ICP: Intracranial pressure; ICU: Intensive care unit; IQR: Interquartile range; GCS: Glasgow Coma Scale; GOSE: Glasgow Outcome Scale Extended; MAP: Mean arterial pressure; LPRx: Long pressure reactivity index; PRx: Pressure reactivity index; TBI: Traumatic brain injury

Acknowledgements

The names of the individual members of the CENTER-TBI High Resolution ICU (HR ICU) Sub-Study Participants and Investigators collaboration group who helped gathering the data for this manuscript should be searchable through their individual PubMed records. Furthermore, we gratefully acknowledge the support from all CENTER-TBI investigators and participants and we are thankful to all participating patients for helping us to improve clinical care and outcome after TBI. Finally, we thank Julia Mattern and Madlen Rädler for their help with the local organization of the CENTER-TBI study at Heidelberg University Hospital.

CENTER-TBI High Resolution ICU (HR ICU) Sub-Study Participants and Investigators: Audny Anke, Department of Physical Medicine and Rehabilitation, University Hospital Northern Norway; Ronny Beer, Department of Neurology, Neurological Intensive Care Unit, Medical University of Innsbruck, Innsbruck, Austria; Bo-Michael Bellander, Department of Neurosurgery & Anesthesia &

Intensive Care Medicine, Karolinska University Hospital, Stockholm, Sweden; Andras Buki, Department of Neurosurgery, University of Pecs and MTA-PTE Clinical Neuroscience MR Research Group and Janos Szentagothai Research Centre, University of Pecs, Hungarian Brain Research Program, Pecs, Hungary; Giorgio Chevallard, NeuroIntensive Care, Niguarda Hospital, Milan, Italy; Arturo Chierogato, NeuroIntensive Care, Niguarda Hospital, Milan, Italy; Giuseppe Citerio, NeuroIntensive Care Unit, Department of Anesthesia & Intensive Care, ASST di Monza, Monza, Italy; and School of Medicine and Surgery, Università Milano Bicocca, Milano, Italy; Endre Czeiter, Department of Neurosurgery, University of Pecs and MTA-PTE Clinical Neuroscience MR Research Group and Janos Szentagothai Research Centre, University of Pecs, Hungarian Brain Research Program (Grant No. KTIA 13 NAP-A-II/8), Pecs, Hungary; Bart Depreitere, Department of Neurosurgery, University Hospitals Leuven, Leuven, Belgium; George Eapen †, Shirin Frisvold, Department of Anesthesiology and Intensive Care, University Hospital Northern Norway, Tromsø, Norway; Raimund Helbok, Department of Neurology, Neurological Intensive Care Unit, Medical University of Innsbruck, Innsbruck, Austria; Stefan Jankowski, Neurointensive Care, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK; Daniel Kondziella, Departments of Neurology, Clinical Neurophysiology and Neuroanesthesiology, Region Hovedstaden Rigshospitalet, Copenhagen, Denmark; Lars-Owe Koskinen, Department of Clinical Neuroscience, Neurosurgery, Umea University Hospital, Umea, Sweden; Geert Meyfroidt, Intensive Care Medicine, University Hospitals Leuven, Leuven, Belgium; Kirsten Moeller, Department Neuroanesthesiology, Region Hovedstaden Rigshospitalet, Copenhagen, Denmark; David Nelson, Department of Neurosurgery & Anesthesia & intensive care medicine, Karolinska University Hospital, Stockholm, Sweden; Anna Piippo-Karjalainen, Helsinki University Central Hospital, Helsinki, Finland; Andreea Radoi, Department of Neurosurgery, Vall d'Hebron University Hospital, Barcelona, Spain; Arminas Ragauskas, Department of Neurosurgery, Kaunas University of technology and Vilnius University, Vilnius, Lithuania; Rahul Raj, Helsinki University Central Hospital, Helsinki, Finland; Jonathan Rhodes, Department of Anaesthesia, Critical Care & Pain Medicine NHS Lothian & University of Edinburgh, Edinburgh, UK; Saulius Rocka, Department of Neurosurgery, Kaunas University of technology and Vilnius University, Vilnius, Lithuania; Rolf Rossaint, Department of Anaesthesiology, University Hospital of Aachen, Aachen, Germany; Juan Sahuquillo, Department of Neurosurgery, Vall d'Hebron University Hospital, Barcelona, Spain; Ana Stevanovic, Department of Anaesthesiology, University Hospital of Aachen, Aachen, Germany; Nina Sundström, Department of Radiation Sciences, Biomedical Engineering, Umea University Hospital, Umea, Sweden; Riikka Takala, Perioperative Services, Intensive Care Medicine, and Pain Management, Turku University Central Hospital and University of Turku, Turku, Finland; Tomas Tamosiutis, Neuro-intensive Care Unit, Kaunas University of Health Sciences, Kaunas, Lithuania; Olli Tenovu, Rehabilitation and Brain Trauma, Turku University Central Hospital and University of Turku, Turku, Finland; Peter Vajkoczy, Neurologie, Neurochirurgie und Psychiatrie, Charité–Universitätsmedizin Berlin, Berlin, Germany; Alessia Vargiolu, NeuroIntensive Care Unit, Department of Anesthesia & Intensive Care, ASST di Monza, Monza, Italy; Rimantas Vilcinis, Department of Neurosurgery, Kaunas University of Health Sciences, Kaunas, Lithuania; Stefan Wolf, Interdisciplinary Neuro Intensive Care Unit, Charité–Universitätsmedizin Berlin, Berlin, Germany.

Authors' contributions

Study design: LR, EB, PS, and AY; ICM+ implementation and algorithm: LR, EB, PS, and MC; data analysis: LR and AY; data interpretation: LR, EB, PS, MC, NS, OS, KZ, AU, and AY; writing the manuscript: LR and AY; reviewing and editing the manuscript: LR, EB, PS, MC, NS, OS, KZ, AU, and AY. All authors read and approved the final manuscript.

Funding

CENTER-TBI was supported by the European Union 7th Framework program (EC grant 602150). Additional funding was obtained from the Hannelore Kohl Stiftung (Germany), OneMind (USA), and Integra LifeSciences Corporation (USA).

Availability of data and materials

Data from the CENTER-TBI study is available to researchers after submitting a detailed study proposal (<https://www.center-tbi.eu/data>) that is approved by the CENTER-TBI management committee. Data from this study is available from the corresponding author upon reasonable request and with permission of the CENTER-TBI management committee.

Ethics approval and consent to participate

The CENTER-TBI study (EC grant 602150) is compliant with all relevant EU and national laws of recruiting centers in regard to privacy, data protection, and ethical standards and in accordance with the Declaration of Helsinki ("Ethical Principles for Medical Research Involving Human Subjects.") Informed consent was obtained from all patients and/or their legal representatives, according to the local legislations, included in this study. Ethical approval was obtained for each recruiting site (see <https://www.center-tbi.eu/project/ethical-approval> for the list of sites, ethical committees, approval numbers, and approval dates).

Consent for publication

Not applicable.

Competing interests

LR received a scholarship from the CENTER-TBI study to visit the Brain Physics Lab in Cambridge. MC and PS receive part of the licensing fee for the ICM+ software. MC is supported by the NIHR Biomedical Research Centre Cambridge. The remaining authors have nothing to disclose.

Author details

¹Department of Neurosurgery, Heidelberg University Hospital, INF 400, 69120 Heidelberg, Germany. ²Brain Physics Laboratory, Division of Neurosurgery, Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK. ³Department of Physiopathology and Transplantation, Milan University, Milan, Italy. ⁴Neuro ICU Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milan, Italy. ⁵Department of Neurosurgery, Klinikum Ludwigsburg, Ludwigsburg, Germany.

Received: 17 December 2019 Accepted: 12 May 2020

Published online: 26 May 2020

References

- Rangel-Castilla L, Gasco J, Nauta HJW, Okonkwo DO, Robertson CS. Cerebral pressure autoregulation in traumatic brain injury. *Neurosurg Focus*. 2008;25:E7 [cited 2019 May 1]. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/18828705>.
- Kelly DF, Martin NA, Kordestani R, Counelis G, Hovda DA, Bergsneider M, et al. Cerebral blood flow as a predictor of outcome following traumatic brain injury. *J Neurosurg*. 1997;86:633–41 [cited 2019 Jul 2]. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/9120627>.
- Werner C, Engelhard K. Pathophysiology of traumatic brain injury. *Br J Anaesth*. 2007;99:4–9 [cited 2019 Jul 2]. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0007091217347840>. Narnia.
- Hlatky R, Valadka AB, Robertson CS. Intracranial pressure response to induced hypertension: role of dynamic pressure autoregulation. *Neurosurgery*. 2005;57:917–23 [cited 2019 Jul 6]. discussion 917–23. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/16284561>.
- Jünger EC, Newell DW, Grant GA, Avellino AM, Ghatan S, Douville CM, et al. Cerebral autoregulation following minor head injury. *J Neurosurg*. 1997;86:425–32 [cited 2019 Jul 6]. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/9046298>.
- Carney N, Totten AM, O'Reilly C, Ullman JS, Hawryluk GWJ, Bell MJ, et al. Guidelines for the management of severe traumatic brain injury, fourth edition. *Neurosurgery*. 2016;80:1 [cited 2019 Jul 2]. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/27654000>.
- Robertson CS, Valadka AB, Hannay HJ, Contant CF, Gopinath SP, Cormio M, et al. Prevention of secondary ischemic insults after severe head injury. *Crit Care Med*. 1999;27:2086–95 [cited 2019 Jul 2]. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/10548187>.
- Lang EW, Kasprzowicz M, Smielewski P, Santos E, Pickard J, Czosnyka M. Short pressure reactivity index versus long pressure reactivity index in the management of traumatic brain injury. *J Neurosurg*. 2015;122:588–94 [cited 2018 Sep 9]. Available from: <http://thejns.org/doi/10.3171/2014.10.JNS14602>. American Association of Neurological Surgeons.
- Czosnyka M, Smielewski P, Kirkpatrick J, Laing RJ, Menon D, Pickard JD. Continuous assessment of the cerebral vasomotor reactivity in head injury. *Neurosurgery*. 1997;41:11–7 [cited 2019 May 1]. discussion 17–9. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/9218290>.
- Sorrentino E, Diedler J, Kasprzowicz M, Budohoski KP, Haubrich C, Smielewski P, et al. Critical thresholds for cerebrovascular reactivity after traumatic brain

- injury. *Neurocrit Care*. 2012;16:258–66 [cited 2019 Apr 30]. Available from: <http://link.springer.com/10.1007/s12028-011-9630-8>. Humana Press Inc.
11. Zeiler FA, Ercole A, Cabeleira M, Zoerle T, Stocchetti N, Menon DK, et al. Univariate comparison of performance of different cerebrovascular reactivity indices for outcome association in adult TBI: a CENTER-TBI study. *Acta Neurochir (Wien)*. 2019;1–11 [cited 2019 May 1]. Available from: <http://link.springer.com/10.1007/s00701-019-03844-1>. Springer Vienna.
 12. Steiner LA, Czosnyka M, Piechnik SK, Smielewski P, Chatfield D, Menon DK, et al. Continuous monitoring of cerebrovascular pressure reactivity allows determination of optimal cerebral perfusion pressure in patients with traumatic brain injury. *Crit Care Med*. 2002;30 Available from: https://journals.lww.com/ccmjournal/Fulltext/2002/04000/Continuous_monitoring_of_cerebrovascular_pressure.2.aspx.
 13. Aries MJH, Czosnyka M, Budohoski KP, Steiner LA, Lavinio A, Koliass AG, et al. Continuous determination of optimal cerebral perfusion pressure in traumatic brain injury. *Crit Care Med*. 2012;40:2456–63 [cited 2019 May 28]. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/22622398>.
 14. Liu X, Maurits NM, Aries MJH, Czosnyka M, Ercole A, Donnelly J, et al. Monitoring of optimal cerebral perfusion pressure in traumatic brain injured patients using a multi-window weighting algorithm. *J Neurotrauma*. 2017;34:3081–8 [cited 2019 Jun 13]. Available from: <http://www.liebertpub.com/doi/10.1089/neu.2017.5003>. Mary Ann Liebert, Inc. 140 Huguenot Street, 3rd Floor New Rochelle, NY 10801 USA.
 15. Zeiler FA, Ercole A, Cabeleira M, Carbonara M, Stocchetti N, Menon DK, et al. Comparison of performance of different optimal cerebral perfusion pressure parameters for outcome prediction in adult traumatic brain injury: a Collaborative European NeuroTrauma Effectiveness Research in Traumatic Brain Injury (CENTER-TBI) study. *J Neurotrauma*. 2019;36:1505–17 [cited 2019 Jun 24]. Available from: <https://www.liebertpub.com/doi/10.1089/neu.2018.6182>. Mary Ann Liebert, Inc., publishers 140 Huguenot Street, 3rd Floor New Rochelle, NY 10801 USA.
 16. Beqiri E, Smielewski P, Robba C, Czosnyka M, Cabeleira MT, Tas J, et al. Feasibility of individualised severe traumatic brain injury management using an automated assessment of optimal cerebral perfusion pressure: the COGITATE phase II study protocol. *BMJ Open*. 2019;9:e030727 [cited 2019 Nov 4]. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/31542757>. British Medical Journal Publishing Group.
 17. Santos E, Diedler J, Sykora M, Orakcioglu B, Kentar M, Czosnyka M, et al. Low-frequency sampling for PRx calculation does not reduce prognostication and produces similar CPPopt in intracerebral haemorrhage patients. *Acta Neurochir (Wien)*. 2011;153:2189–95 [cited 2018 Aug 26]. Available from: <http://link.springer.com/10.1007/s00701-011-1148-5>. Springer Vienna.
 18. Sánchez-Porras R, Santos E, Czosnyka M, Zheng Z, Unterberg AW, Sakowitz OW. 'Long' pressure reactivity index (L-PRx) as a measure of autoregulation correlates with outcome in traumatic brain injury patients. *Acta Neurochir (Wien)*. 2012;154:1575–81 [cited 2018 Aug 26]. Available from: <http://link.springer.com/10.1007/s00701-012-1423-0>. Springer Vienna.
 19. Depreitere B, Güiza F, Van den Berghe G, Schuhmann MU, Maier G, Piper I, et al. Pressure autoregulation monitoring and cerebral perfusion pressure target recommendation in patients with severe traumatic brain injury based on minute-by-minute monitoring data. *J Neurosurg*. 2014;120:1451–7 [cited 2019 Jul 3]. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/24745709>.
 20. Steyerberg EW, Mushkudiani N, Perel P, Butcher I, Lu J, McHugh GS, et al. Predicting outcome after traumatic brain injury: development and international validation of prognostic scores based on admission characteristics. *PLoS Med*. 2008;5:e165 [cited 2019 Jul 31]. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/18684008>. Singer M, editor.
 21. R Core Team. R: A Language and Environment for Statistical Computing [Internet]. Vienna, Austria; 2018. Available from: <https://www.r-project.org/>.
 22. Güiza F, Depreitere B, Piper I, Van den Berghe G, Meyfroidt G. Novel methods to predict increased intracranial pressure during intensive care and long-term neurologic outcome after traumatic brain injury. *Crit Care Med*. 2013;41:554–64 [cited 2019 Jul 6]. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/23263587>.
 23. Zweifel C, Lavinio A, Steiner LA, Radolovich D, Smielewski P, Timofeev I, et al. Continuous monitoring of cerebrovascular pressure reactivity in patients with head injury. *Neurosurg Focus*. 2008;25:E2 [cited 2019 May 3]. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/18828700>.
 24. Aries MJH, Czosnyka M, Budohoski KP, Koliass AG, Radolovich DK, Lavinio A, et al. Continuous monitoring of cerebrovascular reactivity using pulse waveform of intracranial pressure. *Neurocrit Care*. 2012;17:67–76 [cited 2019 Nov 4]. Available from: <http://link.springer.com/10.1007/s12028-012-9687-z>. Humana Press Inc.
 25. Marmarou A, Shulman K, Rosende RM. A nonlinear analysis of the cerebrospinal fluid system and intracranial pressure dynamics. *J Neurosurg*. 1978;48:332–44 [cited 2019 Aug 8]. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/632857>.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

